Ann: Regeneus and AGC collaborate on Progenza in Japan, page-79

Interesting to look at market leader MSB's deal with Mallinckrodt for development and commercialisation of Mesoblast's cell therapy products. Received the $30m today from issuing shares to Mallinckrodt. A good deal still for a $600m MC company.

Interesting when you look at RGS's deal we will receive AU$23m all up with no dilution for one drug targeting Osteo only, just in Japan.

A few more of these deals and licencing fees and surely we can't sit at a $35m MC forever!